摘要
目的观察晚期非小细胞肺癌患者化疗疗效与C反应蛋白(CRP)升高水平的相关性。方法选择2017年1月至2018年8月在广东省中医院肿瘤科接受GC或GP方案化疗的晚期非小细胞肺癌患者60例患者为研究对象,每次疗程治疗前后检测其血清CRP水平,每两次疗程治疗结束后进行影像学检查,根据RECIST标准评估临床疗效,观察CRP水平和化疗疗效的相关性。结果单因素分析显示,不同年龄、性别、吸烟史、原发灶大小、转移灶数目的患者血清CRP水平差异无统计学意义(P>0.05);而不同美国东部肿瘤协作组(ECOG)评分的患者血清CRP水平差异有统计学意义(P<0.05)。单变量生存分析中,ECOG评分和血清CRP水平是影响患者化疗疗效的重要因素(P<0.05)。COX多因素分析结果显示,异常CRP水平、原发灶大小>5 cm、高ECOG评分、转移灶数目>3个是影响非小细胞肺癌预后的危险因素(P<0.05,P<0.01)。结论对于晚期非小细胞肺癌患者,CRP的存在及增强是独立的不良预后因素,CRP水平越高,对化疗反应性越差。
Objective To observe the correlation between serum C-reactive protein(CRP)level and chemotherapy efficacy in patients with advanced non-small cell lung cancer(NSCLC).Methods Sixty patients with advanced NSCLC received chemotherapy of gemcitabine/paclitaxel(GP)and gemcitabine/cisplatin(GC)regimes from January 2017 to August 2018 were enrolled.The serum CRP level was measured before and after each course of treatment;the imaging examinations were performed after every two treatment courses.According to response evaluation criteria in solid tumors(RECIST)criteria,the clinical effect was evaluated,and the correlation between CRP level and chemotherapy effect was observed.Result Single-factor analysis showed that the serum CRP level was not related to age,gender,smoking(all P>0.05),but was related to the score of Eastern Cancer Cooperation Group(ECOG),the size of the primary tumor and the different number of metastases(all P<0.05).In univariate survival analysis,serum CRP level,ECOG score,size of primary lesion and number of metastatic lesions were the important factors affecting the efficacy of chemotherapy.COX multivariate analysis showed that ECOG score,number of metastases and CRP level were the risk factors for the prognosis of NSCLC.Conclusion For advanced NSCLC patients,the presence of CRP is an independent adverse prognostic factor.The higher the CRP level,the worse the response to chemotherapy.
作者
刘丽荣
侯芳芳
张海波
刘译鸿
李文竹
瞿燕春
陈显
LIU Li-rong;HOU Fang-fang;ZHANG Hai-bo;LIU Yi-hong;LI Wen-zhu;QU Yan-chun;CHEN Xian(Department of Oncology,Guangdong Provincial Hospital of Chinese Medicine,Guangzhou,Guangdong 510120,China)
出处
《中国临床研究》
CAS
2020年第6期778-780,共3页
Chinese Journal of Clinical Research
基金
广东省科技厅—广东省中医药科学院联合专项(2014A020221113)
广东省科技厅项目(2014A020221046)
广东省中医院院内专项(YN2016QL04)。
关键词
非小细胞肺癌
晚期
C反应蛋白
化疗
影响因素
Non-small cell lung cancer,advanced
C-reactive protein
Chemotherapy
Affecting factor
